Rocket Pharmaceuticals Inc
RCKT2.510USD
-0.110-4.20%
收盤 05/30, 16:00（美東）報價延遲15分鐘
267.95M總市值
虧損本益比TTM
關於 Rocket Pharmaceuticals Inc 公司
Rocket Pharmaceuticals, Inc. 是一家完全整合的後期生物技術公司。該公司正在推進一系列可持續的試驗性基因療法，旨在糾正複雜和罕見疾病的根本原因。其基於慢病毒 (LV) 載體的基因療法針對血液病，包括針對範康尼貧血症（一種難以治療的遺傳病，會導致骨髓衰竭和潛在的癌症）、白細胞粘附缺陷-I (LAD-I)（一種嚴重的兒科遺傳病，會導致反覆發作且危及生命的感染，這些感染通常是致命的）和丙酮酸激酶缺陷 (PKD)（一種單基因紅細胞疾病，導致紅細胞破壞增加和輕度至危及生命的貧血）的後期項目。該公司還有兩個臨牀階段和一個臨牀前階段的體內腺相關病毒 (AAV) 項目，包括針對 Danon 病、Plakophilin-2 致心律失常性心肌病和 BAG3 擴張型心肌病的項目。
公司簡介
公司代碼RCKT
公司名稱Rocket Pharmaceuticals Inc
上市日期Feb 18, 2015
成立日期1999
CEODr. Gaurav D. Shah, M.D.
員工數量299
證券類型Ordinary Share
年結日Feb 18
公司地址9 Cedarbrook Drive
城市CRANBURY
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編08512
電話16464409100
網址https://www.rocketpharma.com/
公司代碼RCKT
上市日期Feb 18, 2015
成立日期1999
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Gaurav D. Shah, M.D.
Dr. Gaurav D. Shah, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.21M
-0.48%
Dr. Gotham Makker, M.D.
Dr. Gotham Makker, M.D.
Independent Director
Independent Director
621.50K
-24.19%
Dr. Kinnari Patel, Pharm.D.
Dr. Kinnari Patel, Pharm.D.
President, Chief Operating Officer, Head of Research and Development
President, Chief Operating Officer, Head of Research and Development
513.63K
-0.42%
Mr. David P. Southwell
Mr. David P. Southwell
Independent Director
Independent Director
95.12K
-0.04%
Mr. John Militello, CPA
Mr. John Militello, CPA
Principal Accounting Officer, Vice President - Finance, Treasurer
Principal Accounting Officer, Vice President - Finance, Treasurer
57.84K
-1.72%
Mr. Aaron Ondrey
Mr. Aaron Ondrey
Chief Financial Officer, Principal Financial Officer
Chief Financial Officer, Principal Financial Officer
19.52K
-85.77%
Dr. Mikael G. Dolsten, M.D., Ph.D.
Dr. Mikael G. Dolsten, M.D., Ph.D.
Independent Director
Independent Director
14.22K
--
Mr. Pedro Granadillo
Mr. Pedro Granadillo
Independent Director
Independent Director
--
--
Ms. Sarbani Chaudhuri
Ms. Sarbani Chaudhuri
Chief Commercial and Medical Affairs Officer
Chief Commercial and Medical Affairs Officer
--
--
Dr. Jonathan Schwartz, M.D.
Dr. Jonathan Schwartz, M.D.
Chief Medical and Gene Therapy Officer
Chief Medical and Gene Therapy Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Gaurav D. Shah, M.D.
Dr. Gaurav D. Shah, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.21M
-0.48%
Dr. Gotham Makker, M.D.
Dr. Gotham Makker, M.D.
Independent Director
Independent Director
621.50K
-24.19%
Dr. Kinnari Patel, Pharm.D.
Dr. Kinnari Patel, Pharm.D.
President, Chief Operating Officer, Head of Research and Development
President, Chief Operating Officer, Head of Research and Development
513.63K
-0.42%
Mr. David P. Southwell
Mr. David P. Southwell
Independent Director
Independent Director
95.12K
-0.04%
Mr. John Militello, CPA
Mr. John Militello, CPA
Principal Accounting Officer, Vice President - Finance, Treasurer
Principal Accounting Officer, Vice President - Finance, Treasurer
57.84K
-1.72%
Mr. Aaron Ondrey
Mr. Aaron Ondrey
Chief Financial Officer, Principal Financial Officer
Chief Financial Officer, Principal Financial Officer
19.52K
-85.77%
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
股東統計
佔比
RTW Investments L.P.
16.42%
Wellington Management Company, LLP
6.64%
The Vanguard Group, Inc.
6.13%
BlackRock Institutional Trust Company, N.A.
5.71%
Maverick Capital, Ltd.
5.15%
Other
59.96%
持股股東
股東統計
佔比
RTW Investments L.P.
16.42%
Wellington Management Company, LLP
6.64%
The Vanguard Group, Inc.
6.13%
BlackRock Institutional Trust Company, N.A.
5.71%
Maverick Capital, Ltd.
5.15%
Other
59.96%
股東類型
股東統計
佔比
Investment Advisor/Hedge Fund
51.25%
Investment Advisor
20.03%
Hedge Fund
18.39%
Research Firm
4.48%
Individual Investor
2.60%
Bank and Trust
1.28%
Venture Capital
1.25%
Private Equity
1.13%
Pension Fund
0.17%
機構持股
更新時間: 3月4日 週二
更新時間: 3月4日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q1
469
117.28M
110.07%
+11.74M
2024Q4
469
115.66M
108.78%
+9.90M
2024Q3
442
99.39M
108.64%
-6.54M
2024Q2
434
97.04M
106.63%
-8.16M
2024Q1
431
98.54M
108.92%
-3.20M
2023Q4
427
94.76M
105.15%
-7.91M
2023Q3
413
94.89M
105.90%
+6.62M
2023Q2
408
81.61M
101.38%
-10.66M
2023Q1
419
83.81M
105.83%
-4.94M
2022Q4
433
80.68M
102.32%
-522.65K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
RTW Investments L.P.
17.69M
16.59%
--
--
Dec 31, 2024
Wellington Management Company, LLP
14.00M
13.13%
+2.75M
+24.49%
Dec 31, 2024
The Vanguard Group, Inc.
6.56M
6.16%
+1.04M
+18.84%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
5.63M
5.28%
+524.20K
+10.26%
Dec 31, 2024
Maverick Capital, Ltd.
5.20M
4.88%
+1.08M
+26.23%
Dec 31, 2024
Westfield Capital Management Company, L.P.
4.71M
4.42%
+220.78K
+4.91%
Dec 31, 2024
State Street Global Advisors (US)
3.46M
3.24%
+356.06K
+11.48%
Dec 31, 2024
Suvretta Capital Management, LLC
2.57M
2.41%
+2.57M
--
Dec 31, 2024
Janus Henderson Investors
4.00M
3.76%
+2.11M
+111.03%
Dec 31, 2024
T. Rowe Price Associates, Inc.
3.09M
2.9%
-34.49K
-1.10%
Dec 31, 2024
查看更多
持股ETF
更新時間: 5月6日 週二
更新時間: 5月6日 週二
機構名稱
佔比
Virtus LifeSci Biotech Clinical Trials ETF
1.28%
Global X Genomics & Biotechnology ETF
1.18%
Harbor Health Care ETF
0.64%
Tema Cardiovascular and Metabolic ETF
0.35%
Main Thematic Innovation ETF
0.34%
SPDR S&P Biotech ETF
0.22%
Direxion Daily S&P Biotech Bull 3X Shares
0.14%
Federated Hermes MDT Small Cap Core ETF
0.12%
Franklin Genomic Advancements ETF
0.1%
ProShares Ultra Nasdaq Biotechnology
0.07%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
佔比1.28%
Global X Genomics & Biotechnology ETF
佔比1.18%
Harbor Health Care ETF
佔比0.64%
Tema Cardiovascular and Metabolic ETF
佔比0.35%
Main Thematic Innovation ETF
佔比0.34%
SPDR S&P Biotech ETF
佔比0.22%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.14%
Federated Hermes MDT Small Cap Core ETF
佔比0.12%
Franklin Genomic Advancements ETF
佔比0.1%
ProShares Ultra Nasdaq Biotechnology
佔比0.07%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
